Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA.
Curr Oncol Rep. 2022 Sep;24(9):1121-1131. doi: 10.1007/s11912-022-01250-y. Epub 2022 Apr 11.
This review aims to discuss recent advances in elucidating the tumor microenvironment (TME) in B lymphomas and resultant novel therapeutic development.
While tumor morphology, immunophenotype, and molecular profile are established factors that predict outcome and guide therapy, the prognostic impact of infiltrating, non-tumor cells is now emerging. This is simultaneously facilitating the development of new therapies that target non-tumor cells. The tumor microenvironment (TME) is a complex ecosystem composed of infiltrating cells and byproducts, extracellular matrix, and other non-cellular tissues. In lymphomas, our current understanding of the role of the TME is principally informed by studies in B-cell lineage diseases. As we improve our understanding of lymphoma biology, the importance of the impact of the non-tumor cell microenvironment is becoming more apparent. This lays the foundation for the investigation and development of novel therapies and combination strategies that target non-tumor cells and tumor cell/non-tumor cell interactions.
本文旨在讨论阐明 B 细胞淋巴瘤肿瘤微环境（TME）的最新进展及其带来的新的治疗策略。
虽然肿瘤形态、免疫表型和分子特征是预测预后和指导治疗的既定因素，但浸润性非肿瘤细胞的预后影响现在正在显现。这同时促进了针对非肿瘤细胞的新疗法的发展。肿瘤微环境（TME）是一个由浸润细胞和代谢产物、细胞外基质和其他非细胞组织组成的复杂生态系统。在淋巴瘤中，我们对 TME 作用的理解主要来自于 B 细胞谱系疾病的研究。随着我们对淋巴瘤生物学认识的提高，非肿瘤细胞微环境的影响变得越来越明显。这为研究和开发针对非肿瘤细胞以及肿瘤细胞/非肿瘤细胞相互作用的新型治疗方法和联合策略奠定了基础。
